Monographie - Oxaliplatin

Poslední aktualizace :
08/05/2024

Oxaliplatin

Chemický vzorec

Obchodní název

Trade names are indicative and excipients composition can be different depending on the country and manufacturers

Axiplatin	NÏmecko
Bendaplatin	NÏmecko
Bioezulen	BrazÌlie
Celdach	Peru
Crisapla	Chile, Ekvádor, Venezuela
Crisatinox	Turecko
Dabenzol	Argentina, Ekvádor
Dacplat	Argentina
Eloxarin	Ekvádor
Eloxatin	äpanÏlsko, Belgie, BrazÌlie, Chile, Egypt, Írán, Itálie, Kolumbie, Lucembursko, Malajsie, Mexiko, Norsko, Nový Zéland, Peru, Portugalsko, Rakousko, Rumunsko, Spojené arabské emiráty, Švédsko, Švýcarsko, Thajsko, Turecko, USA, Velká Británie, Venezuela
Eloxatine	Francie, Maroko, Švýcarsko
Entia	Kolumbie, Mexiko
Euroxaliplatine	NÏmecko
Glenoxal	Peru
Goxyral	Argentina, Ekvádor
Kebir	Argentina, Peru
Linoxa	Turecko
Lisix	Chile
Metaplatin	Argentina
Oliptino	Argentina
Onicol	Chile, Peru
Oxalibbs	BrazÌlie
Oxaliplan	NÏmecko
Riboxatin	NÏmecko

Odkazy : Oxaliplatin

	Typ	Uveřejnění
1662	Noviny	Trissel LA, Saenz CA, Ingram DS, Ogundele AB. Compatibility screening of oxaliplatin during simulated Y-site administration with other drugs. J Oncol Pharm Practice 2002 ; 8: 33-37.
1950	Noviny	Trissel LA, Yanping Z. Physical and chemical stability of palonosetron HCl with cisplatin, carboplatin and oxaliplatin during simulated Y-site administration. J Oncol Pharm Practice 2004 ; 10: 191-195.
2207	Noviny	André A, Cisternino S, Roy A.L, Chiadmi F, Schlatter J, Agranat P, Fain O, Fontan J.E. Stability of oxaliplatin in infusion bags containing 5% dextrose injection. Am J Health-Syst Pharm 2007 ; 64, 18: 1950-1954.
2239	Noviny	Wang C, Zhang X, Liu HY. Determination of the stability of oxaliplatin for injection by dual wavelength spectrophotometry. Chinese J New Drugs 2005 ; 14, 2: 189-191.
2253	Noviny	Curis E, Provost K, Bouvet D, Nicolis I, Crauste-manciet S, Brossard D, B?nazeth S. Carboplatin and oxaliplatin decomposition in chloride medium, monitored by XAS. J Synchrotron Rad 2001 ; 8: 716-718.
2258	Laboratoř	Stability of oxaliplatin "Ebewe" lyophilisate after reconstitution. Ebewe Pharma 2007
2259	Laboratoř	Stability of oxaliplatin "Ebewe" lyophilisate infusion solutions. Ebewe Pharma 2007
2321	Noviny	Junker A, Roy S, Desroches M.C, Moussay C, Berhoune M, Bellanger A, Fernandez C,Farinotti R. Stability of Oxaliplatin Solution. Ann Pharmacotherapy 2009 ; 43,2: 390-391.
2791	Noviny	Mehta A.M,.Van den Hoven J.M, Rosing H,.Hillebrand M.J.X, Nuijen B,. Huitema A.D.R, Beijnen J.H,.Verwaal V.J. Stability of oxaliplatin in chloride-containing carrier solutions used in hyperthermic intraperitoneal chemotherapy. Int J Pharm 2015 ; 479 : 23-27.
2883	Noviny	Eiden C, Philibert L, Bekhtari K, Poujol S, Malosse F, Fr?d?ric Pinguet F. Physicochemical stability of oxaliplatin in 5% dextrose injection stored in polyvinyl chloride, polyethylene, and polypropylene infusion bags. Am J Health-Syst Pharm 2009 ; 66, 21: 1929-1933.
3369	Laboratoř	Levofolinate de sodium Medac - Résumé des caractéristiques du produits MEDAC France 2011
3413	Noviny	Jerremalm E, Hedeland M, Wallin I, Bondesson U, Ehrsson H. Oxaliplatin degradation in the presence of chloride: Identification and cytotoxicity of the monochloro monooxalato complex. Pharm Res 2004 ; 21, 5: 891-894.
3602	Laboratoř	Mesna (Uromitexan®)- Summary of Product Characteristics Baxter SAS 2013
3634	Laboratoř	Oxaliplatine (Oxaliplatine Accord®) - Résumé des caractéristiques du produit Accord Healthcare 2011
3670	Noviny	Sewell G, Massimini M. Studies on the stability and compatibility of cytotoxic drug infusion with the Tevadaptor system. EJOP 2014 ; 8, 3: 26-30.
3706	Noviny	Escudero-Ortiz V, Duart-Duart M.J, P?rez-Ruixo C, P?rez-Ruixo J.J, Valenzuela B. Estudio de estabilidad de oxaliplatino y doxorrubicina para su administración intraperitoneal con hipertermia. Farm Hosp 2014 ;38, 3:154-161
4004	Noviny	Krämer I, Sarakbi I, Thiesen J, Mainz. Physikalisch-chemische Stabilität von Oxaliplatin-beta-Infusionslösungskonzentrat und Infusionslösungen in 5 % Glucose in Polyolefin-Infusionsbeuteln. Krankenhauspharmazie 2017 ;38,7:334?340.

Mentions Légales